ISSN: 2450-7741
eISSN: 2300-4460
OAI
DOI: 10.18276/frfu.2016.4.82/2-66
Issue archive /
4/2016
Polityka refundacji wyrobów leczniczych w krajach europejskich
(The Reimbursement Policy of Pharmaceuticals in European Countries)
| Authors: | Justyna Kujawska |
| Keywords: | pharmaceutical pricing policy pharmaceutical reimbursement policy spending on pharmaceutical products |
| Data publikacji całości: | 2016 |
| Page range: | 9 (773-781) |
Abstract
Purpose – Analysis of refunds policy and financing of pharmaceuticals in European countries. Design/methodology/approach – Analysis of the literature on reimbursement policies of pharmaceutical products. Analysis of statistical information on the public and private financing of pharmaceutical products purchase. Findings – Public financing of pharmaceuticals is dominating in Western Europe. Deficiencies in public funding are often covered by private health insurance. In Central and Eastern Europe people are likely to use generic than innovative pharmaceutical products and private financing is larger than public. The low share of private insurance in CEE countries means that spending on pharmaceutical products are a significant part of household expenditures. Originality/value – There are few studies on cross-country in terms of pharmaceuticals reimbursement.
Download file
Article file
Bibliography
| 1. | Carone G., Schwierz Ch., Xavier A. (2012). Cost-containment policies in public pharmaceutical spending in the EU. Economic Papers, 461. |
| 2. | Cutler M.D., Everett W. (2010). Thinking outside the pillbox – medication adherence as a priority for health care reform. The New England Journal of Medicine, 362 (17), 1553–1055. |
| 3. | Enterprice and Industry. Pobrano z: http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/structimpact_pharmaprices_032011_en.pdf. |
| 4. | Eurostat database. Pobrano z: http://ec.europa.eu/eurostat/data/database. |
| 5. | Henry D., Lexchin J. (2002). The pharmaceutical industry as a medicines provider. The Lancet, 360 (9345), 1590–1595. |
| 6. | IMS (2013). Global Pharmaceuticals. Marketing Channel Reference. Pobrano z: http://raport2014.pelion.eu/pl. |
| 7. | Kanavos P., Schurer W., Vogler S. (2011). The Pharmaceutical Distribution Chain in the European Union: Structure and Impact on Pharmaceutical Prices’. Emint. Final report. |
| 8. | Leopold Ch., Mantel-Teeuwisse A.K., Vogler S., Valkova S., de Joncheere K., Leufkens H.G.M., Wagner A.K., Ross-Degnan D., Laing R. (2014). Effect of the economic recession on pharmaceutical policy and medicine sales in eight European countries. Bulletin of the World Health Organization, 92 (9), 630–640D. |
| 9. | OECD (2008). Pharmaceutical Pricing Policies in a Global Market. OECD Health Policy Studies. OECD.Stat. Pobrano z: stats.oecd.org (12.04.2016). |
| 10. | PMR (2015). Rynek produktów OTC w Polsce 2015. Prognozy rozwoju na lata 2015–2020. Pobrano z: http://forumfarmaceutyczne.blog.pl/2015/08/20/w-2015-roku-rynek-produktow-otc-w-polsce-powroci-na-sciezke-wzrostu. |
| 11. | Puig-Junoy J., García-Gómez P., Casado-Marín D. (2011). Free Medicines thanks to Retirement: Moral Hazard and Hospitalization Offsets in an NHS. Tinbergen Institute Discussion Paper, 108 (3), 1–33. |
| 12. | Ustawa z dnia 12 maja 2011 r. o refundacji leków, środków spożywczych specjalnego przeznaczenia żywieniowego oraz wyrobów medycznych. Dz.U. 2011, nr 122n poz. 696 z późn. zm. |
| 13. | Vogler S., Habimana K. (2014). Pharmaceutical pricing policies in European countries. Vienna: Gesundheit Österreich Forschungs- und Planungs GmbH. |
| 14. | Vogler S., Habl C., Leopold C., Rosian-Schikuta I., de Joncheere K., Lyager T.T. (2008). Pharmaceutical Pricing and Reimbursement Information. PPRI Report. Vienna: ÖBIG. |
| 15. | Vogler S., Österle A., Mayer S. (2015). Inequalities in medicine use in Central Eastern Europe: an empirical investigation of socioeconomic determinants in eight countries. International Journal for Equity in Health, 14 (124), 1–19. |
| 16. | Vogler S., Zimmermann N., Leopold C., Joncheere K.D. (2011). Pharmaceutical policies in European countries in response to the global financial crisis. Southern Medical Review, 4 (2), 69–79. |
| 17. | Xu K., Evans D.B., Carrin G., Aguilar-Rivera A.M. (2005). Designing health financing systems to reduce catastrophic health expenditure. Technical Brief For Policy-Makers, 2. |
| 18. | Zuidberg C. (2010). The pharmaceutical system of the Netherland. Vienna. |